|

Catadegbrutinib Clinical Trials

1 actively recruiting trial across 1 location

Also known as: BGB-16673

Pipeline

Phase 2: 1

Top Sponsors

  • Massachusetts General Hospital1

Indications

  • Small Lymphocytic Lymphoma (SLL)1
  • Chronic Lymphocytic Leukemia1
  • Cancer1

Boston, Massachusetts1 trial

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Massachusetts General Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.